Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dynavax Announces HEPLISAV-B™ is Now Available in the United States for the Prevention of Hepatitis B in Adults
HEPLISAV-B is the First and Only Two-Dose Vaccine in U.S. for Hepatitis B Prevention in Adults
View HTML
Toggle Summary Dynavax to Present at J.P. Morgan 36th Annual Healthcare Conference
BERKELEY, Calif. , Jan. 04, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that Eddie Gray , Dynavax's chief executive officer, will present at the J.P. Morgan 36th Annual Healthcare Conference next week in San Francisco, CA.
View HTML
Toggle Summary Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BERKELEY, CA -- (Marketwired) -- 12/05/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that on November 28, 2017 the Compensation Committee of Dynavax's Board of Directors approved (i) the grant of inducement stock options to purchase an aggregate 73,800 shares of common stock
View HTML
Toggle Summary Dynavax to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
BERKELEY, CA -- (Marketwired) -- 11/27/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that Eddie Gray , Dynavax's chief executive officer, will present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference this week in Boston, MA.
View HTML
Toggle Summary Dynavax Announces FDA Approval of HEPLISAV-B(TM) for Prevention of Hepatitis B in Adults
First and Only Two-Dose Vaccine in United States for Prevention of Hepatitis B in AdultsFirst New Hepatitis B Vaccine in United States in More than 25 YearsCompany to Host Conference Call/Webcast Today at 5:00 p.m. ET
View HTML
Toggle Summary Dynavax Reports Third Quarter 2017 Financial Results
BERKELEY, CA -- (Marketwired) -- 11/03/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2017 . Cash, cash equivalents and marketable securities were $191.7 million at September 30, 2017 compared to $81.4 million at
View HTML
Toggle Summary Dynavax Initiates Clinical Trial in Non-Small Cell Lung Cancer with a Novel Inhaled TLR9 Agonist in Combination with Anti-PD-1 Therapy
Dynavax Expands its TLR9 Agonist Platform in Combination with Anti-PD-1 Therapy to a Third Tumor Type
View HTML
Toggle Summary Dynavax to Present at Upcoming Investor Conferences
BERKELEY, CA -- (Marketwired) -- 09/05/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the company will present at two upcoming investor conferences in September. NewsMakers in the Biotech Industry Investor Conference Friday, September 8, 2017 in New York at 8:30 a.m.
View HTML
Toggle Summary Dynavax Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
BERKELEY, CA -- (Marketwired) -- 08/15/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the completion of an underwritten public offering of 5,750,000 shares of its common stock, including 750,000 shares sold pursuant to the full exercise of an over-allotment option previously
View HTML
Toggle Summary Dynavax Prices Public Offering of Common Stock
BERKELEY, CA -- (Marketwired) -- 08/09/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the pricing of a previously announced underwritten public offering of 5,000,000 shares of its common stock, offered at a price to the public of $15.00 per share.
View HTML